Eosinophilic Gastroenteritis Market (7MM) is Expected to Witness Significant Growth During the Forecast Period (2026-2036) | DelveInsight

DelveInsight's "Eosinophilic Gastroenteritis Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of Eosinophilic Gastroenteritis, historical and forecasted epidemiology, and Eosinophilic Gastroenteritis Market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Eosinophilic Gastroenteritis Market Report @ https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Eosinophilic Gastroenteritis Market Report
• In April 2026, Kate Farms Inc (Responsible Party) announced result of Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis Induction of Remission.
• In March 2026, Eupraxia Pharmaceuticals Inc. announced result of A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104GI in Adults With Eosinophilic Esophagitis (RESOLVE).
• There are currently no FDA-approved therapies indicated specifically for eosinophilic gastroenteritis, with treatment relying on off-label approaches including corticosteroids, proton pump inhibitors, dietary interventions, leukotriene inhibitors, and immunosuppressive agents.
• The United States accounts for the highest number of diagnosed eosinophilic gastroenteritis cases across the 7MM, driven by higher disease awareness, access to specialist gastroenterology care, and increasing use of endoscopy with biopsy-based diagnostic evaluation.
• Eosinophilic gastroenteritis frequently affects younger and middle-aged adults, though it can occur across all age groups.
• The disease shows a male predominance, with men representing a greater proportion of diagnosed cases compared to females.
• The mucosal subtype accounts for the majority (50-100%) of diagnosed cases, followed by muscularis (10%-30%) and subserosal (10%-15%) subtypes.
• The Eosinophilic Gastroenteritis Companies include Sanofi and Regeneron Pharmaceuticals, among others.
• Promising Eosinophilic Gastroenteritis Therapy includes Dupilumab (DUPIXENT), among others.

Get a Free sample for the Eosinophilic Gastroenteritis Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Eosinophilic Gastroenteritis?
Eosinophilic gastroenteritis is a rare, chronic inflammatory gastrointestinal disorder characterized by eosinophilic infiltration of the gastrointestinal tract in the absence of secondary causes of eosinophilia such as parasitic infections, malignancies, or systemic inflammatory disorders. The disease can affect multiple layers of the gastrointestinal wall, including the mucosal, muscular, and serosal layers, leading to heterogeneous clinical manifestations depending on the site and depth of involvement. It is considered part of the broader spectrum of eosinophilic gastrointestinal diseases (EGIDs) and is frequently associated with allergic conditions such as asthma, food allergies, eczema, and other atopic disorders. Clinical manifestations vary widely and commonly include abdominal pain, nausea, vomiting, diarrhea, bloating, weight loss, anemia, gastrointestinal bleeding, and nutritional deficiencies, often resulting in substantial quality-of-life impairment. Diagnosis remains challenging due to its nonspecific presentation and overlap with other gastrointestinal disorders; endoscopy with multiple gastrointestinal biopsies remains the cornerstone of diagnosis, supported by complete blood count with eosinophil evaluation, serum IgE assessment, allergy testing, and imaging studies.

Eosinophilic Gastroenteritis Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of Eosinophilic Gastroenteritis
• Gender-specific Diagnosed Prevalent Cases of Eosinophilic Gastroenteritis
• Age-specific Diagnosed Prevalent Cases of Eosinophilic Gastroenteritis
• Treated Cases for Eosinophilic Gastroenteritis

Download the report to understand which factors are driving Eosinophilic Gastroenteritis market trends @ https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Eosinophilic Gastroenteritis Approved Therapies
There are currently no FDA-approved therapies indicated specifically for eosinophilic gastroenteritis. Treatment remains largely dependent on off-label approaches, including corticosteroids, proton pump inhibitors, dietary interventions, leukotriene inhibitors, immunosuppressive agents, and symptomatic management strategies, with glucocorticoids serving as the mainstay treatment.

Eosinophilic Gastroenteritis Pipeline Analysis
• Dupilumab (DUPIXENT): Regeneron Pharmaceuticals/Sanofi
Dupilumab is a fully human monoclonal antibody that blocks IL-4 and IL-13 signaling, two key drivers of type 2 inflammation implicated in eosinophilic gastroenteritis. By targeting these pathways, Dupixent aims to reduce eosinophilic inflammation, improve gastrointestinal symptoms, and achieve sustained disease control without broadly suppressing the immune system. The drug successfully completed a Phase II clinical trial in eosinophilic gastroenteritis in 2024 and is currently being evaluated in an ongoing Phase II study in adult and adolescent patients with eosinophilic gastritis, with or without eosinophilic duodenitis.

Eosinophilic Gastroenteritis Companies
Sanofi, Regeneron Pharmaceuticals, and others

Eosinophilic Gastroenteritis Market Outlook
Eosinophilic gastroenteritis has no approved disease-specific therapies, leaving significant unmet medical needs. Current management relies on off-label corticosteroids, dietary interventions, proton pump inhibitors, and immunosuppressants, which often result in relapse and long-term treatment burden. While several investigational candidates have been discontinued, dupilumab has emerged as the leading pipeline therapy. Its targeted mechanism offers the potential for durable disease control, reduced corticosteroid dependence, and improved long-term treatment outcomes.

Scope of the Eosinophilic Gastroenteritis Market Report
• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Coverage: 7MM
• Eosinophilic Gastroenteritis Companies: Sanofi, Regeneron Pharmaceuticals, and others
• Eosinophilic Gastroenteritis Therapies: Dupilumab (DUPIXENT), and others
• Eosinophilic Gastroenteritis Therapeutic Assessment: Eosinophilic Gastroenteritis current marketed and emerging therapies
• Eosinophilic Gastroenteritis Market Dynamics: Eosinophilic Gastroenteritis market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Eosinophilic Gastroenteritis Unmet Needs, KOL's views, Analyst's views, Eosinophilic Gastroenteritis Market Access and Reimbursement

To know more about Eosinophilic Gastroenteritis companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Eosinophilic Gastroenteritis Market Overview at a Glance
7. Disease Background and Overview of Eosinophilic Gastroenteritis
8. Epidemiology and Patient Population of Eosinophilic Gastroenteritis
9. Patient Journey of Eosinophilic Gastroenteritis
10. Emerging Drugs
11. Eosinophilic Gastroenteritis: 7MM Analysis
12. Unmet Needs of Eosinophilic Gastroenteritis
13. SWOT Analysis of Eosinophilic Gastroenteritis
14. KOL Views of Eosinophilic Gastroenteritis
15. Market Access and Reimbursement of Eosinophilic Gastroenteritis
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.